PMID- 34882269
OWN - NLM
STAT- MEDLINE
DCOM- 20220330
LR  - 20220714
IS  - 2366-0058 (Electronic)
VI  - 47
IP  - 2
DP  - 2022 Feb
TI  - Longitudinal evaluation of apparent diffusion coefficient values as a predictor 
      of Prostate Cancer Research International Active Surveillance reclassification.
PG  - 814-826
LID - 10.1007/s00261-021-03372-6 [doi]
AB  - PURPOSE: This study aimed to evaluate the effectiveness of apparent diffusion 
      coefficient (ADC) parameters in distinguishing between Prostate Cancer Research 
      International Active Surveillance (PRIAS) non-reclassification and 
      reclassification groups during active surveillance (AS) of prostate cancer. 
      METHODS: We included 55 patients who fulfilled the PRIAS criteria and 
      underwent >/= 2 magnetic resonance imaging (MRI) including diffusion-weighted 
      imaging with an interval of </= 3 years between baseline and second MRI. A 
      mono-exponential fitting model was used to automatically create ADC maps with 
      minimum b-values of 0 and maximum of 2000 s/mm(2). For detectable lesions on ADC 
      maps, the lesions were manually segmented on each slice of the ADC maps. For 
      undetectable lesions, the corresponding normal-appearing zone of the lobe on each 
      slice of ADC maps was segmented. The ADC data for each slice were summed to 
      obtain the 25th, 50th, and 75th percentile ADC values of the histogram at 
      baseline and second MRI. These ADC parameters at baseline and second MRI, and the 
      changes of ADC parameters from baseline to second MRI were compared between PRIAS 
      non-reclassification and reclassification groups. RESULTS: The PRIAS 
      reclassification group had significantly lower 25th, 50th, and 75th percentile 
      ADC values at second MRI compared to the non-reclassification group. The 
      non-reclassification group had significantly lower changes in ADC values in these 
      percentiles compared to the reclassification group. CONCLUSION: The ADC 
      parameters at second MRI and the changes from baseline to second MRI may be 
      effective distinguishing factors between PRIAS non-reclassification and 
      reclassification groups.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Ota, Eri
AU  - Ota E
AD  - Department of Diagnostic Radiology, Tohoku University Graduate School of 
      Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.
FAU - Mori, Naoko
AU  - Mori N
AUID- ORCID: 0000-0002-8700-9731
AD  - Department of Diagnostic Radiology, Tohoku University Graduate School of 
      Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan. 
      naokomori7127@gmail.com.
FAU - Yamashita, Shinichi
AU  - Yamashita S
AD  - Department of Urology, Tohoku University Graduate School of Medicine, 1-1 
      Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.
FAU - Mugikura, Shunji
AU  - Mugikura S
AD  - Department of Diagnostic Radiology, Tohoku University Graduate School of 
      Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.
AD  - Division of Image Statistics, Tohoku Medical Megabank Organization, Tohoku 
      University, Sendai, Japan.
FAU - Ito, Akihiro
AU  - Ito A
AD  - Department of Urology, Tohoku University Graduate School of Medicine, 1-1 
      Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.
FAU - Takase, Kei
AU  - Takase K
AD  - Department of Diagnostic Radiology, Tohoku University Graduate School of 
      Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.
LA  - eng
PT  - Journal Article
DEP - 20211209
PL  - United States
TA  - Abdom Radiol (NY)
JT  - Abdominal radiology (New York)
JID - 101674571
SB  - IM
MH  - Diffusion Magnetic Resonance Imaging/methods
MH  - Humans
MH  - Magnetic Resonance Imaging/methods
MH  - Male
MH  - Prostate/pathology
MH  - *Prostatic Neoplasms/diagnostic imaging/pathology
MH  - Retrospective Studies
MH  - *Watchful Waiting
OTO - NOTNLM
OT  - Active surveillance
OT  - Apparent diffusion coefficient
OT  - Diffusion-weighted imaging
OT  - Prostate cancer
OT  - Reclassification
EDAT- 2021/12/10 06:00
MHDA- 2022/03/31 06:00
CRDT- 2021/12/09 12:25
PHST- 2021/10/24 00:00 [received]
PHST- 2021/11/29 00:00 [accepted]
PHST- 2021/11/28 00:00 [revised]
PHST- 2021/12/10 06:00 [pubmed]
PHST- 2022/03/31 06:00 [medline]
PHST- 2021/12/09 12:25 [entrez]
AID - 10.1007/s00261-021-03372-6 [pii]
AID - 10.1007/s00261-021-03372-6 [doi]
PST - ppublish
SO  - Abdom Radiol (NY). 2022 Feb;47(2):814-826. doi: 10.1007/s00261-021-03372-6. Epub 
      2021 Dec 9.